Affimed N.V. (LON:0HL9)
0.8119
+0.0323 (4.14%)
At close: Apr 24, 2025
Affimed Employees
Affimed had 76 employees as of December 31, 2023. The number of employees decreased by 143 or -65.30% compared to the previous year.
Employees
76
Change (1Y)
-143
Growth (1Y)
-65.30%
Revenue / Employee
61.72K GBP
Profits / Employee
-766.12K GBP
Market Cap
11.51M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,315 |
Affimed News
- 4 days ago - Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting - GlobeNewsWire
- 7 days ago - Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 4 weeks ago - Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting - GlobeNewsWire
- 7 weeks ago - Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire
- 4 months ago - Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC) - Benzinga
- 4 months ago - Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - GlobeNewsWire
- 4 months ago - Affimed reports data from mid-stage study of its lymphoma treatment - Seeking Alpha
- 4 months ago - Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - GlobeNewsWire